Actuate Therapeutics | 10-Q: Quarterly report

SECSep 24 16:07 ET · Announcements

Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

GlobeNewswireSep 23 08:00 ET

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination With FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

GlobeNewswireSep 16 08:00 ET

Alta Copper Announces Non-Brokered Financing With Fortescue Ltd.

AccesswireSep 11 08:30 ET

Actuate Gets FDA Orphan Designation for Elraglusib in Soft Tissue Sarcomas

WSJSep 11 08:18 ET

Express News | Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

ReutersSep 11 08:00 ET